Payment overview · 2025
General Payments
$896.44
42 reported records · 15 companies
Healthcare provider profile · identity verified
Samuel Andrew Hale
Allopathic & Osteopathic Physicians|Family Medicine · LUBBOCK, TX · NPI 1851369185
Verified facts
What the public records show
CMS Open Payments records show Samuel Andrew Hale received $896.44 in general payments during 2025 across 42 reported records.
ABBVIE INC. accounted for 33.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Linzess, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $300.13 | 33.5% | 11 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $142.08 | 15.8% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $81.41 | 9.1% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $75.44 | 8.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.73 | 6.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.92 | 5.2% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.61 | 3.6% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $26.25 | 2.9% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $24.57 | 2.7% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $21.25 | 2.4% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $19.78 | 2.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.60 | 2.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.34 | 2.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17.12 | 1.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.21 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $896.44 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $142.08 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $136.05 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $133.80 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $60.31 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $46.92 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $46.92 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $45.75 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $42.86 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.15 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $32.61 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.56 | 2 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $26.25 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $24.57 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $21.25 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.47 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $11.98 | 4 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 98 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 96 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
82 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
98 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
96 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
61 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 980 | 179 |
| Atorvastatin Calcium | Atorvastatin Calcium | 662 | 136 |
| Lisinopril | Lisinopril | 358 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 340 | 73 |
| Alprazolam | Alprazolam | 331 | 71 |
| Diclofenac Sodium | Diclofenac Sodium | 325 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 293 | 63 |
| Azithromycin | Azithromycin | 282 | 196 |
| Amlodipine Besylate | Amlodipine Besylate | 279 | 65 |
| Amitriptyline Hcl | Amitriptyline Hcl | 258 | 46 |
| Metformin Hcl | Metformin Hcl | 255 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 243 | 51 |
| Citalopram Hbr | Citalopram Hydrobromide | 230 | 51 |
| Prednisone | Prednisone | 228 | 146 |
| Metoprolol Succinate | Metoprolol Succinate | 226 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 218 | 51 |
| Gabapentin | Gabapentin | 217 | 34 |
| Allopurinol | Allopurinol | 206 | 38 |
| Losartan Potassium | Losartan Potassium | 204 | 44 |
| Montelukast Sodium | Montelukast Sodium | 195 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 44 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 173 | 59 |
| Tramadol Hcl | Tramadol Hcl | 172 | 40 |
| Valsartan | Valsartan | 165 | 36 |
| Furosemide | Furosemide | 155 | 43 |
| Meloxicam | Meloxicam | 149 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 53 |
| Glipizide | Glipizide | 132 | 28 |
| Enalapril Maleate | Enalapril Maleate | 124 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 122 | 17 |
| Cefadroxil | Cefadroxil | 113 | 86 |
| Cephalexin | Cephalexin | 110 | 87 |
| Zolpidem Tartrate | Zolpidem Tartrate | 104 | 18 |
| Simvastatin | Simvastatin | 102 | 22 |
| Celecoxib | Celecoxib | 101 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 19 |
| Ezetimibe | Ezetimibe | 101 | 24 |
| Estradiol | Estradiol | 99 | 22 |
| Omeprazole | Omeprazole | 99 | 25 |
| Amoxicillin | Amoxicillin | 98 | 68 |
| Farxiga | Dapagliflozin Propanediol | 98 | 17 |
| Famotidine | Famotidine | 97 | 29 |
| Mounjaro | Tirzepatide | 96 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 91 | 70 |
| Potassium Chloride | Potassium Chloride | 88 | 24 |
| Synthroid | Levothyroxine Sodium | 82 | 20 |
| Lovastatin | Lovastatin | 77 | 17 |
| Temazepam | Temazepam | 77 | 12 |
| Trazodone Hcl | Trazodone Hcl | 73 | 15 |
| Buspirone Hcl | Buspirone Hcl | 72 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 11 |
| Fenofibrate | Fenofibrate | 66 | 13 |
| Eszopiclone | Eszopiclone | 64 | 14 |
| Glipizide Er | Glipizide | 64 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 62 | 51 |
| Eliquis | Apixaban | 61 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 59 | 36 |
| Pregabalin | Pregabalin | 58 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 58 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 57 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 57 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 53 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 52 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | suppressed |
| Clonazepam | Clonazepam | 51 | suppressed |
| Cefprozil | Cefprozil | 48 | 44 |
| Ozempic | Semaglutide | 47 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 45 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 44 | suppressed |
| Chlorthalidone | Chlorthalidone | 43 | suppressed |
| Levofloxacin | Levofloxacin | 43 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 40 | suppressed |
| Glyburide | Glyburide | 40 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 39 | 21 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Acyclovir | Acyclovir | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Ondansetron Odt | Ondansetron | 38 | 23 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | suppressed |
| Telmisartan | Telmisartan | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | 14 |
| Fluconazole | Fluconazole | 36 | 15 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 36 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Gemfibrozil | Gemfibrozil | 34 | suppressed |
| Lorazepam | Lorazepam | 34 | suppressed |
| Olanzapine | Olanzapine | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 33 | suppressed |
| Nabumetone | Nabumetone | 33 | suppressed |
| Ramipril | Ramipril | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Cefdinir | Cefdinir | 32 | 24 |
| Linzess | Linaclotide | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Dexamethasone | Dexamethasone | 29 | 29 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Carvedilol | Carvedilol | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Carisoprodol | Carisoprodol | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | 13 |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 16 | 15 |
| Triazolam | Triazolam | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Mesalamine Dr | Mesalamine | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Sotalol Af | Sotalol Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $896.44 · 42 records | ABBVIE INC. | AIRSUPRA, AREXVY, BREZTRI, Dyanavel XR, FARXIGA, GEMTESA, LINZESS, MOUNJARO, NEFFY, NURTEC ODT, QULIPTA, Quviviq, SHINGRIX, Symbravo, TONMYA, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error